



Legal Division
Patents & Trademarks
D377/AP6A-1

Abbott Laboratories
100 Abbott Park Road
Abbott Park, IL 60064-6008

Telephone: (847) 935-7835
FAX: (847) 938-2623

FACSIMILE COVER SHEET

DATE: January 11, 2005

TO: Office of Initial Patent Examination's Filing Receipt Corrections
US PTO Office

FROM: Kalim S. Fuzail
Patents and Trademarks
D-0377, AP6A-1
Telephone: (847) 935-7835

PHONE NUMBER OF TELECOPY MACHINE: 703-746-9195

TOTAL NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 5

MESSAGE:

S/N 10/733,946
Applicant(s): D. DeGoey, et al.
Transmittal Letter - 1 pg. (in duplicate)
Corrected Updated Filing Receipt - 2 pgs.

THIS TRANSMISSION IS INTENDED ONLY FOR THE INDIVIDUAL(S) TO WHOM IT IS ADDRESSED.
It may contain confidential information, attorney work product, or other privileged material. If you are not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this transmission is strictly prohibited. If you have received this transmission in error, please notify us immediately by telephone at (847) 935-7562 and return the transmission to us at the address listed above.
©Abbott Laboratories, 1991. All rights reserved. If YOU DO NOT RECEIVE ALL PAGES AS INDICATED, PLEASE CALL (847) 935-7562

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: DeGoey, et al.
SERIAL NO.: 10/733,946
FILED: December 11, 2003
FOR: HIV PROTEASE INHIBITING
COMPOUNDS
EXAMINER: (not assigned)
GROUP ART NO.: 1642
CASE NO.: 7263.US.01
Date: January 11, 2005

Certificate of Facsimile Transmission under 37 CFR §1.8(a):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via facsimile, said transmission to be completed before midnight Eastern time on the date shown below, addressed to the following recipient:

Office of Initial Patent Examination's Filing Receipt
Corrections
US PTO Office
Alexandria, VA 22313-1450

Recipient Telefax Number: 703-746-9195

Date of Facsimile: January 12, 2005

Wanda E. Smith
Wanda E. Smith

TRANSMITTAL LETTER

Office of Initial Patent Examination's Filing Receipt Corrections
US PTO Office
Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith is a corrected Filing Receipt of D. DeGoey, *et al.*, for HIV PROTEASE INHIBITING COMPOUNDS, the specification of which was filed on December 11, 2003, and received Serial No. 10/733,946. Please note that the Updated Filing Receipt incorrectly listed the filing date as 12/10/03, when in actuality, it should be 12/11/03.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR 1.16, as well as any patent application processing fees under 37 CFR 1.17 associated with this communication for which full payment has not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

ABBOTT LABORATORIES
Customer Number: 23492
Telephone: (847) 935-7835
Facsimile: (847) 938-2623

Respectfully Submitted,
DeGoey, et al.

Kahim S. Fuzail
Kahim S. Fuzail
Registration No. 45,805
Attorney for Applicants

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

APPLICANT: DeGoey, et al.
SERIAL NO.: 10/733,946
FILED: December 11, 2003
FOR: HIV PROTEASE INHIBITING
COMPOUNDS
EXAMINER: (not assigned)
GROUP ART NO.: 1642
CASE NO.: 7263.US.01
Date: January 11, 2005

Certificate of Facsimile Transmission under 37
CFR §1.8(a):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via facsimile, said transmission to be completed before midnight Eastern time on the date shown below, addressed to the following recipient:

Office of Initial Patent Examination's Filing Receipt
Corrections
US PTO Office
Alexandria, VA 22313-1450

Recipient Telefax Number: 703-746-9195

Date of Facsimile: January 12, 2005

Wanda E. Smith
Wanda E. Smith

TRANSMITTAL LETTER

Office of Initial Patent Examination's Filing Receipt Corrections
US PTO Office
Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith is a corrected Filing Receipt of D. DeGoey, *et al.*, for HIV PROTEASE INHIBITING COMPOUNDS, the specification of which was filed on December 11, 2003, and received Serial No. 10/733,946. Please note that the Updated Filing Receipt incorrectly listed the filing date as 12/10/03, when in actuality, it should be 12/11/03.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR 1.16, as well as any patent application processing fees under 37 CFR 1.17 associated with this communication for which full payment has not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

ABBOTT LABORATORIES
Customer Number: 23492
Telephone: (847) 935-7835
Facsimile: (847) 938-2623

Respectfully Submitted,
DeGoey, et al.

Kahm S. Fuzail
Kahm S. Fuzail
Registration No. 45,805
Attorney for Applicants




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/733,946	12/11/2003 12/10/2003	1642	3108	7263.US.01		98	5

23492
ROBERT DEBERARDINE
ABBOTT LABORATORIES
100 ABBOTT PARK ROAD
DEPT. 377/AP6A
ABBOTT PARK, IL 60064-6008



CONFIRMATION NO. 8723

UPDATED FILING RECEIPT



OC00000014172083

Date Mailed: 10/22/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt Incorporating the requested corrections (if appropriate).

Applicant(s)

- David A. DeGoey, Salem, WI;
- Charles A. Flentge, Salem, WI;
- William J. Fiosl, Evanston, IL;
- David J. Grampovnik, Waukegan, IL;
- Dale J. Kempf, Libertyville, IL;
- Larry L. Klein, Lake Forest, IL;

Power of Attorney: The patent practitioners associated with Customer Number 23492.

Domestic Priority data as claimed by applicant

Foreign Applications

If Required, Foreign Filing License Granted: 03/18/2004

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/733,946**

Projected Publication Date: 06/16/2005

Non-Publication Request: No

Early Publication Request: No

Title

HIV protease inhibiting compounds

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).